GSK · Pharma and healthcare · one day
GSK (GSK): news on Wednesday 18 November 2026
News from the 24 hours to Wednesday morning, 18 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Most coverage focused on US approval of Nelkarmi, the second lung cancer medicine to come from the Nuvalent acquisition, which advances its oncology push. A few items on patent expiry concerns, job cuts and a small share price dip moderated the tone.
What drove it
- Nelkarmi FDA approval
- oncology growth plan
- patent cliff concerns
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Thu 12 Nov | +4.5 | 12 |
| Fri 13 Nov | +4.2 | 14 |
| Sat 14 Nov | +9.2 | 20 |
| Sun 15 Nov | +7.0 | 6 |
| Mon 16 Nov | +2.5 | 4 |
| Tue 17 Nov | +5.7 | 8 |
| Wed 18 Nov | +7.5 | 36 |
6 stories · 36 headlines · strongest first
Pharma and healthcare on 18 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Nelkarmi receives US accelerated approval for ALK-positive lung cancer +9.522 headlines today · Outlets report that Nelkarmi (neladalkib), the second lung cancer medicine GSK has gained from buying Nuvalent, received accelerated US approval. | ||
| +10.0 | Approved drug seen as having very large sales potential. | |
| +10.0 | Second product from major acquisition gains US clearance. | |
| +10.0 | Second approval from large acquisition supports its value. | |
| +10.0 | Second approval from large acquisition supports its value. | |
| +10.0 | Second acquired lung cancer drug clears regulator. | |
| +10.0 | Regulatory clearance for second cancer medicine from acquired portfolio. | |
| +10.0 | Approval bolsters its growing cancer franchise. | |
| +10.0 | Approval from major deal adds to oncology line-up. | |
| +9.7 | Acquisition delivers another marketed oncology product. | |
| +9.7 | Second lung cancer product cleared following acquisition. | |
| +9.5 | Regulator clears therapy gained through takeover. | |
| +9.5 | US regulator clears new lung cancer medicine. | |
| +9.2 | Accelerated US clearance for new lung cancer treatment. | |
| +9.2 | Approval for previously treated ALK-positive patients. | |
| +9.2 | US regulator approves its lung cancer medicine. | |
| +9.2 | Company announces US approval for advanced lung cancer treatment. | |
| +9.0 | Approval addresses resistance in a lung cancer subtype. | |
| +8.7 | Conditional US clearance for lung cancer drug. | |
| +8.7 | Conditional US clearance for lung cancer drug. | |
| +8.7 | Conditional US approval for lung cancer drug. | |
| +8.3 | US regulators clear its cancer medicine. | |
| +8.3 | Brief report of US regulatory clearance. | |
| GSK presents growth plan at Jefferies healthcare conference +0.77 headlines today · Coverage of GSK's conference presentation covers its 2031 sales ambition, savings, Phase III starts and the HIV patent cliff. | ||
| +8.3 | Cost savings and pipeline starts underpin ambitious long-term sales goal. | |
| +5.8 | Management says growth plan is accelerating. | |
| −5.0 | Job cuts and restructuring raise pressure on shares. | |
| −5.0 | Concern over expiring patents despite oncology plans. | |
| +3.3 | Finance chief relies on oncology to offset forecast shortfall. | |
| −1.7 | Growth plan discussed alongside patent expiry challenge. | |
| −0.8 | Ambitious sales target tempered by HIV patent expiry concerns. | |
| GSK share outlook and market commentary +0.53 headlines today · 7 in all, since 17 November · Pieces report small share-price falls and discuss whether to sell GSK shares. | ||
| −3.3 | Shares dipped despite decent quarterly performance. | |
| −1.7 | Small premarket share price decline. | |
| −0.8 | Adviser question about selling holdings; neutral commentary. | |
| Jefferies keeps Neutral rating on GSK +0.42 headlines today · Jefferies reaffirmed its Neutral rating, with some profit-taking in the shares noted. | ||
| +0.8 | Shares eased as investors banked gains despite supportive broker. | |
| 0.0 | Broker keeps middling view unchanged. | |
| EU committee backs GSK's Bexsero meningitis B booster +9.21 headline today · 14 in all, since 14 November · A piece asks whether Bexsero can extend its reach after the CHMP recommendation. | ||
| +6.7 | European committee backs booster for meningitis vaccine. | |
| GSK executive share purchases +2.71 headline today · 2 in all, since 14 November · A director and executives acquired ADSs through dividend reinvestment. | ||
| +0.3 | Routine insider share acquisition via dividend reinvestment. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.